Does mean platelet volume (MPV) increase after iron infusion in patients with iron deficiency anemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Mean Platelet Volume (MPV) Does Not Increase After Iron Infusion

MPV levels remain unchanged following iron replacement therapy in patients with iron deficiency anemia, regardless of whether treatment achieves partial or complete response. 1

Key Evidence on MPV Response

The most recent high-quality study directly addressing this question found no change in MPV levels before and after iron treatment in patients with iron deficiency anemia and normal platelet counts 1. Specifically:

  • MPV levels remained stable at approximately 8.8-8.9 fL both before and after iron therapy, with no significant difference between partial responders (hemoglobin 10-12 g/dL) and complete responders (hemoglobin >12 g/dL) 1
  • This finding held true regardless of the route of iron administration (oral or intravenous) 2

What Actually Changes: Platelet Count and Other Parameters

While MPV remains stable, iron replacement therapy causes significant changes in other platelet parameters:

Platelet Count Decreases

  • Platelet count decreases in approximately 72% of patients following iron replacement therapy 2
  • Median platelet count drops from 299 × 10⁹/L at baseline to 265 × 10⁹/L at 3 months post-treatment (p < 0.0001) 2
  • This decrease occurs even in patients without baseline thrombocytosis 2

Thrombocytosis Resolution

  • Thrombocytosis (platelets >400 × 10⁹/L) is present in approximately 22% of iron deficiency anemia patients at baseline 2
  • Following iron replacement, thrombocytosis resolves in most patients, with only 5% maintaining elevated counts at 3 months 2

Other Platelet Parameters

  • Plateletcrit and platelet distribution width (PDW) decrease following iron therapy 1
  • There is an inverse correlation between MPV and platelet count (r = -0.5, p < 0.001), meaning as platelet count decreases with treatment, MPV tends to remain stable or show minimal compensatory changes 1

Clinical Mechanism

The relationship between iron deficiency and platelet parameters is mediated through:

  • Serum iron and transferrin saturation are the key iron metabolism parameters affecting platelet count 3
  • More severe iron deficiency correlates with higher platelet counts 3
  • The mechanism may involve increased erythropoietin production in iron deficiency states, which can stimulate megakaryopoiesis 4

Important Clinical Caveats

Intravenous iron administration may actually decrease platelet counts more than oral iron in some contexts. Data from hemodialysis patients showed platelet counts decreased by 29,000/μL with IV iron versus no change without iron (p = 0.017) 4. This suggests IV iron may have additional effects on platelet production beyond simply correcting iron deficiency.

The absence of MPV change does not mean platelet function is normal. Studies show that platelet aggregation (particularly collagen-induced and ADP-induced) is actually diminished in iron deficiency anemia and improves with treatment 5, even though MPV remains unchanged.

Monitoring Recommendations

When treating iron deficiency anemia:

  • Monitor platelet count at 3 months post-treatment, as this is when the most significant changes occur 2
  • Do not rely on MPV as a marker of treatment response, as it does not change significantly 1
  • Expect platelet count normalization in patients with baseline thrombocytosis within 3 months of adequate iron replacement 2

References

5
Research

Diminished platelet aggregation in patients with iron deficiency anemia.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 1999

Related Questions

What is the significance of elevated Thyroid-Stimulating Hormone (TSH) levels, thrombocytosis (high platelet count), and erythrocytosis (high Red Blood Cell (RBC) count) following intravenous iron infusion?
How should a 51-year-old woman with iron‑deficiency anemia (hemoglobin 9.5 g/dL, hematocrit 31.5 %, MCV 71.8 fL, MCH 21.6 pg, ferritin 5 ng/mL, serum iron 24 µg/dL) be managed?
In a 77‑year‑old male with hypertension, Barrett’s esophagus, COPD, interstitial lung disease, scleroderma, abdominal aortic aneurysm, chronic aspirin use, sucralfate, and proton‑pump inhibitor therapy, and laboratory findings of low hemoglobin, low serum iron, low ferritin, high total iron‑binding capacity, low transferrin saturation, microcytosis, elevated red cell distribution width, leukocytosis, and thrombocytosis, what are the likely causes of his anemia?
What is the treatment approach for anemia with thrombocytopenia (low platelet count)?
What do the lab results (hemoglobin 10.2 g/dL, low mean corpuscular hemoglobin, low mean corpuscular hemoglobin concentration, platelet count 408 ×10⁹/L) indicate in a 37‑year‑old woman with a history of iron‑deficiency anemia?
Do occupational therapists (OTs) manage lymphedema in patients with a history of cancer or those who have undergone surgery or radiation?
What is the recommended treatment for a patient with a 5th metatarsal base fracture, considering factors such as fracture severity, overall health status, and activity level?
What medication can falsely lower the Bispectral Index (BIS) in pediatric patients?
What causes elevated mean platelet volume (MPV) in a patient with iron deficiency anemia?
What induction agent should be used in the emergency department to avoid hypotension and cardiac arrest in critically ill or injured patients, particularly those with cardiovascular disease or who are hemodynamically unstable?
What is the likely diagnosis and management for an adult patient with elevated Cancer Antigen 125 (CA125) levels and peritoneal omental caking?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.